COMMUNIQUÉS West-GlobeNewswire

Ambio Life Sciences Partners with Athletes for Care to Provide Medically Supervised Ibogaine Programming and Support to Professional Athletes Living with Traumatic Brain Injury
15/10/2026
• Mounting research links repeated head trauma in professional sports to lasting brain injury, with few effective treatment options for retired athletes • An initial cohort of three NHL and two NFL alumni independently [...]
A Child's Light Partners with coeo Therapy to Expand Rapid-Response Youth Trauma Care into Montgomery County
15/10/2026
The Strategic Regional Expansion Bridges Crucial Mental Health Access Gaps, Connecting Traumatized Youth with Relational, Whole-Person Healing Within Days COLLEGEVILLE, PA, Oct. 15, 2026 (GLOBE NEWSWIRE) -- A Child's [...]
Selon un nouveau sondage commandé par la National Lung Health Alliance, les Canadiennes et les Canadiens appuient en forte majorité une loi pour une génération sans fumée (aussi appelée « génération sans tabac »)
15/10/2026
96 % des personnes sondées estiment qu’il est important d’éviter que les enfants ne commencent à fumer ou à vapoter, tandis que 76 % appuient l’initiative pour une génération sans fumée, cette même mesure audacieuse que [...]
Canadians Overwhelmingly Support a Smoke-Free Generation Law, a New Poll Commissioned by National Lung Health Alliance Finds
15/10/2026
96% say preventing children from taking up smoking or vaping is important, while 76% support a Smoke-Free Generation, the same bold action the U.K. passed into law OTTAWA, Ontario, Oct. 15, 2026 (GLOBE NEWSWIRE) -- A [...]
Chiesi Global Rare Diseases Supports Continued Generation of Real-World and Scientific Evidence in Epidermolysis Bullosa (EB), Including New Data Presented at 2026 PeDRA Annual Conference
15/10/2026
-- New mechanistic research and clinician-reported real-world experience adds to the evolving evidence base for birch triterpenes in EB -- -- Chiesi proudly marks EB Awareness Week (October 25–31) with continued [...]
Chiesi Global Rare Diseases Supports Continued Generation of Real-World and Scientific Evidence in Epidermolysis Bullosa (EB), Including New Data Presented at 2026 PeDRA Annual Conference
15/10/2026
-- New mechanistic research and clinician-reported real-world experience adds to the evolving evidence base for birch triterpenes in EB -- -- Chiesi proudly marks EB Awareness Week (October 25–31) with continued [...]
Neumarker and Cortica Enter Strategic Partnership to Advance Precision Autism Care
15/10/2026
Strategic Collaboration Focused on Precision Autism Care Partnership Brings Together Neumarker’s AI Platform and Cortica’s Clinical Expertise MOUNTAIN VIEW, Calif. and SAN DIEGO, Oct. 15, 2026 (GLOBE NEWSWIRE) -- [...]
NHS Announces £838m GP IT Framework
15/10/2026
15 October 2026 DXS INTERNATIONAL PLC (AQSE: DXSP) NHS Announces £838m GP IT Framework DXS International plc ( AQSE: DXSP ), the UK healthcare technology provider, welcomes the announcement from NHS England which has [...]
Correction: DXS International PLC (AQSE: DXSP) NHS Announces £838m GP IT Framework
15/10/2026
15 October 2026 DXS INTERNATIONAL PLC (AQSE: DXSP) NHS Announces £838m GP IT Framework DXS International plc ( AQSE: DXSP ), the UK healthcare technology provider, welcomes the announcement from NHS England which has [...]
Profusa Receives ISO 13485:2016 Certificate from GMED
15/10/2026
Providing a Foundational Quality Management System (QMS) for Commercialization Certificate issued by GMED, an EU MDR notified body, following the positive certification decision previously announced ISO 13485 [...]
Krystal Biotech Announces Positive Clinical Data for New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression in Patients with Gorlin Syndrome
15/10/2026
Over 80% of assessed basal cell carcinoma lesions regressed across three Gorlin syndrome patients treated with KB113 Substantial regression was observed in lesions not directly injected with KB113, consistent with [...]
Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes
15/10/2026
Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes The Phase 1 trial will assess the safety and clinical [...]
OMass Therapeutics Announces $310 Million Series C Financing to Advance Portfolio of Small Molecule Therapeutics in Endocrinology and Immunology
15/10/2026
Financing co-led by new investors Bain Capital Life Sciences, Forbion and Novo Holdings, with strong participation from additional new and existing investors Proceeds to advance MC2 receptor antagonist OMS1620 through [...]
R1 Therapeutics to present Phase 2b trial-in-progress poster for AP306 at ASN Kidney Week 2026
15/10/2026
Poster will outline the design of R1’s ongoing global Phase 2b trial evaluating AP306 in patients with hyperphosphatemia AP306 is a potential first-in-class, oral, non-binder small molecule designed to inhibit all three [...]
Eclipse Life Sciences Announces Positive Topline Results from Phase 2 BETTIS-1 Study Evaluating EC-104 for Diabetic Macular Edema (DME)
15/10/2026
RESEARCH TRIANGLE PARK, N.C., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Eclipse Life Sciences, Inc. , a privately held clinical-stage biopharmaceutical company developing next-generation therapies for retinal diseases, today [...]
Why Is Weight Loss Different During Menopause? Common Myths Debunked
15/10/2026
Myth: Menopause weight gain is inevitable. Truth: Acceleration is not inevitable. Body composition science addresses the underlying shift. Myth: Eating less and moving more is enough in midlife. Truth: Without a [...]
Ligand to Report Third Quarter 2026 Financial Results on October 29, 2026
15/10/2026
JUPITER, Fla., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report third quarter 2026 financial results on Thursday, October 29, 2026. The company [...]
Salvia BioElectronics Initiates Pivotal Study with First Patient in the U.S. Receiving Ultra Thin Neuromodulation Implant for Resistant Migraine
15/10/2026
RECLAIM-II evaluates Salvia’s purpose-built neuromodulation system for migraine as a potential new preventive treatment for adults with resistant migraine. Eindhoven, the Netherlands and Newnan, Georgia, 15 October 2026 [...]
Cellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at the International Workshop for Waldenström Macroglobulinemia
15/10/2026
Subgroup analysis of patients who received Bruton Tyrosine Kinase inhibitor (BTKi) treatment immediately prior to iopofosine I 131 achieved 87.5% ORR, 79.2% MRR and 100% CBR with median DOR of 16 months Initiation and [...]

Pages